D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Cognitive Studies, Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | September 2002 |
| End Date: | December 2010 |
| Contact: | Rajiv Radhakrishnan, MD |
| Email: | rajiv.radhakrishnan@yale.edu |
| Phone: | 203-932-5711 |
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA)
receptor function in the brain and thereby increasing the capacity of the brain to both form
new connections and strengthen existing connections, schizophrenic patients may derive both
greater and sustained benefit from cognitive retraining.
receptor function in the brain and thereby increasing the capacity of the brain to both form
new connections and strengthen existing connections, schizophrenic patients may derive both
greater and sustained benefit from cognitive retraining.
Patients with schizophrenia or schizoaffective disorder who are currently receiving
antipsychotic medication will be randomly assigned in a double-blind manner to receive
either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a
non-interactive placebo for 12 weeks.
antipsychotic medication will be randomly assigned in a double-blind manner to receive
either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a
non-interactive placebo for 12 weeks.
Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder
Exclusion
- Pregnant or lactating
We found this trial at
2
sites
Click here to add this to my saved trials
VA Connecticut Healthcare System VA Connecticut encompasses an inpatient facility and Ambulatory Care Center in...
Click here to add this to my saved trials